Celularity Inc.
CELUCelularity Inc. in brief
Celularity Inc. is a listed company in the Biotechnology industry, based in Florham Park, New Jersey, USA. Its market value was $28 M on 30 October 2026, which makes it the 23,327th largest listed company in the world and the 4,061st largest in the USA on this site. In the year to December 2025 it had sales of $27 M and a net loss of $92 M. It employs about 288 people and Robert J. Hariri is its chief executive. Its largest product and service lines by sales in 2025 were License Royalty and Other (30%). Its shares trade under the symbol CELU (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Celularity Inc.
Celularity is a Clinical Stage Biotechnology company developing targeting indications across cancer, immunologic, infectious and degenerative diseases. The company estimated annual revenue is currently 32.2 million USD. The headquarters is in USA.
Celularity Inc. timeline
- 2018
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2019
- 🔔Initial public offering as GX Acquisition Corp.Final prospectus filed with the SEC on 21 May 2019; shares registered for exchange trading on 17 May 2019. The blank-check company later merged with the business that carries the name today.
- 2021
- ✎Renamed Celularity IncFormerly GX Acquisition Corp..
- 2024
- 💰Record revenue of $54 millionFY2024, the highest of the 6 years on record.
Events of Celularity Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,102 (Jan 2022) · #3,845 (Dec 2022) · #4,500 (Jul 2023) · #4,005 (Jan 2024) · #2,219 (Mar 2026) · #3,948 (Aug 2026) · #3,878 (Oct 2026) · #4,064 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 1.5×
- Price / book
- —
- Free cash flow yield
- -23.8%
- Net margin (TTM)
- -245.8%
- Operating margin
- -230.9%
- Return on equity
- —
- Liabilities / assets
- 135.5%
- Revenue growth
- -51.0%
- R&D / revenue
- 56.6%
- Revenue per employee
- $92 K
- Profit per employee
- $-318 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $27M | -51.0% | $-61M | $-92M | -345.5% |
| Dec 2024 | $54M | +138.1% | $-38M | $-58M | -106.8% |
| Dec 2023 | $23M | +26.6% | $-192M | $-196M | -862.1% |
| Dec 2022 | $18M | -15.7% | $-26M | $14M | 78.9% |
| Dec 2021 | $21M | +49.4% | $-109M | $-100M | -469.2% |
| Dec 2020 | $14M | — | $-152M | $-208M | -1458.2% |
| Dec 2019 | — | — | $-2M | $6M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-13M | — | — | $-3.59 | — |
| Dec 2024 | $-6M | $0M | $-7M | $-2.64 | — |
| Dec 2023 | $-39M | $1M | $-40M | $-11.02 | — |
| Dec 2022 | $-138M | $5M | $-143M | $0.95 | — |
| Dec 2021 | $-110M | $6M | $-116M | $-1.49 | — |
| Dec 2020 | $-63M | $28M | $-91M | $-11.31 | — |
| Dec 2019 | $-1M | — | — | $0.10 | — |
Quarterly results
Latest quarter to Jun 2026: revenue $5M (-5.4% on a year earlier), net income $1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 10, 2026DEF 14AProxy statement
- Oct 29, 20268-KCurrent reportOther events
- Oct 20, 202610-QQuarterly report · period to Jun 2026
- Oct 20, 202610-K/AAnnual report (amended) · period to Dec 2025
- Sep 29, 20268-KCurrent reportDirectors or officers changed
- Sep 29, 202610-QQuarterly report · period to Mar 2026
- Sep 28, 20268-KCurrent reportMaterial agreement · New financial obligation · Unregistered share sale · Directors or officers changed
- Sep 14, 20268-KCurrent reportOther events
- Aug 7, 20268-KCurrent reportDirectors or officers changed
- Jul 29, 20268-KCurrent reportListing notice
- Jun 30, 20268-KCurrent reportMaterial agreement · New financial obligation · Directors or officers changed
- Jun 25, 20268-KCurrent reportDirectors or officers changed
Official filings of Celularity Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $27 M
- Operating income
- $-61 M
- Net income
- $-92 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $107 M
- Total liabilities
- $145 M
- Total equity
- $-38 M
As of December-2025
Top 33 institutional investors in Celularity Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | C V Starr & Co Inc | 764,069 | 0 (0.00%) | 2.35% | $1 M | Nov 10, 2026 |
| 2 | Vanguard Capital Management LLC | 646,444 | +25,339 (+4.08%) | 1.99% | $1 M | Nov 13, 2026 |
| 3 | Geode Capital Management, LLC | 167,150 | 0 (0.00%) | 0.52% | $0 M | Nov 6, 2026 |
| 4 | Vanguard Fiduciary Trust Co | 121,516 | +41,642 (+52.13%) | 0.37% | $0 M | Nov 13, 2026 |
| 5 | UBS Group AG | 80,075 | +78,395 (+4666.37%) | 0.25% | $0 M | Nov 10, 2026 |
| 6 | BlackRock, Inc. | 76,359 | 0 (0.00%) | 0.24% | $0 M | Nov 13, 2026 |
| 7 | State Street Corp | 57,830 | 0 (0.00%) | 0.18% | $0 M | Nov 12, 2026 |
| 8 | Northern Trust Corp | 49,874 | +5,711 (+12.93%) | 0.15% | $0 M | Nov 16, 2026 |
| 9 | Biltmore Family Office, LLC | 35,000 | 0 (0.00%) | 0.11% | $0 M | Nov 3, 2026 |
| 10 | HB Wealth Management, LLC | 31,915 | 0 (0.00%) | 0.10% | $0 M | Oct 23, 2026 |
| 11 | Sky Investment Group LLC | 29,920 | New | 0.09% | $0 M | Oct 30, 2026 |
| 12 | Royal Bank Of Canada | 18,000 | 0 (0.00%) | 0.06% | $0 M | Nov 16, 2026 |
| 13 | Jane Street Group, LLC | 17,403 | -11,310 (-39.39%) | 0.05% | $0 M | Nov 12, 2026 |
| 14 | IPG Investment Advisors LLC | 17,169 | 0 (0.00%) | 0.05% | $0 M | Oct 30, 2026 |
| 15 | Mercer Global Advisors Inc /adv | 15,200 | New | 0.05% | $0 M | Nov 16, 2026 |
| 16 | BFC Planning, Inc. | 7,713 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 17 | Tower Research Capital LLC (TRC) | 3,323 | -1,788 (-34.98%) | 0.01% | $0 M | Nov 16, 2026 |
| 18 | Wells Fargo & Company/mn | 2,500 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 19 | Vanguard Global Advisers, LLC | 2,315 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 20 | SBI Securities Co., Ltd. | 1,882 | -402 (-17.60%) | 0.01% | $0 M | Oct 22, 2026 |
| 21 | Caldwell Sutter Capital, Inc. | 1,000 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 22 | CoreCap Advisors, LLC | 500 | 0 (0.00%) | 0.00% | $0 M | Oct 8, 2026 |
| 23 | HighMark Wealth Management LLC | 441 | 0 (0.00%) | 0.00% | $0 M | Nov 17, 2026 |
| 24 | Global Retirement Partners, LLC | 300 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 25 | Financial Perspectives, Inc | 171 | 0 (0.00%) | 0.00% | $0 M | Nov 3, 2026 |
Show all 33: investors 26 to 33
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Valley National Advisers Inc | 100 | 0 (0.00%) | 0.00% | $0 M | Oct 23, 2026 |
| 27 | BNP Paribas Financial Markets | 99 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 28 | Jones Financial Companies Lllp | 82 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 29 | United Financial Planning Group LLC | 19 | 0 (0.00%) | 0.00% | $0 M | Nov 4, 2026 |
| 30 | Jpmorgan Chase & Co | 16 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 31 | Harbour Investments, Inc. | 15 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 32 | Barclays PLC | 4 | New | 0.00% | $0 M | Nov 6, 2026 |
| 33 | Danske Bank A/s | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
Mutual funds holding Celularity Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 455,049 | $0 M | 1.4% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 104,816 | $0 M | 0.32% | <0.01% | +22% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 166,056 | $0 M | 0.51% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 21,176 | $0 M | 0.07% | <0.01% | +6.7% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 20,677 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 8,438 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 6 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Celularity Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Stephen BrigidoPres., Functional Regeneration | Option exercise | +821 | — | — | 9,742 | Form 4 |
| filed | Robert J. HaririChief Executive Officer, Director | Option exercise | +3,281 | — | — | 2.85 M | Form 4 |
| filed | John R. HainesSenior Exec Vice President | Option exercise | +1,641 | — | — | 30,762 | Form 4 |
| filed | Robert J. HaririChief Executive Officer, Director | Shares withheld for tax | -1,182 | $1.280 | $2 K | 2.85 M | Form 4 |
| filed | Stephen BrigidoPres., Functional Regeneration | Shares withheld for tax | -268 | $1.280 | $343 | 9,474 | Form 4 |
| filed | John R. HainesSenior Exec Vice President | Shares withheld for tax | -583 | $1.280 | $746 | 30,179 | Form 4 |
| filed | Geoffrey LingDirector | Grant or awardamended | +19,231 | — | — | 256,026 | Form 4/A |
| filed | Vincent LeVienDirector | Grant or awardamended | +28,847 | — | — | 153,847 | Form 4/A |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Celularity Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2020 | Q4 2021 | $0M |
Trading halts
- 2024-11-15 14:56 UTC, code LUDP, resumed 15:01 UTC
- 2024-11-14 20:25 UTC, code LUDP, resumed 20:30 UTC
Fails to deliver
- : 4,254 shares at $0.85
- : 6,254 shares at $0.94
- : 406 shares at $0.79
- : 74,477 shares at $0.75
- : 54,289 shares at $0.98
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Celularity Inc. scorecard#
Passes 4 of the 19 checks that could be worked out: strongest in growth (3 of 6), weakest in profitability (0 of 4). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✓Price to sales below its peers' median1.5×Price to sales 1.5× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-23.8%Free cash flow is -23.8% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth3 of 6
- ✗Revenue grew in the newest year-51.0%Revenue down 51.0% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years13.9%13.9% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median13.9%13.9% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-3.59 vs -2.64Diluted EPS -3.59 in fiscal 2025 against -2.64 the year before (report's currency).
- ✓Net income higher than five years earlier-$92 M-$92 M in fiscal 2025 against -$208 M in 2020.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
Profitability0 of 4
- ✗Profitable in the newest year-$92 MNet income -$92 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-230.9%-230.9% against Biotechnology's median of -60.5% (243 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-230.9%-230.9% in fiscal 2025 against -142.4% in 2022.
Financial health0 of 3
- ✗Short-term assets cover short-term liabilities0.1×Current ratio 0.15 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-15.22Z-score -15.22 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year16.9%Diluted shares up 16.9% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Celularity Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -230.9% | -60.5% | |
| Net margin | -345.5% | -68.9% | |
| Revenue growth, 3 years a year | 13.9% | 12.9% | |
| Revenue growth | -51.0% | 15.8% |
1of 8on the Piotroski tests of financial strength
- Revenue fell 51.0% against the year before.
- Net loss of $92 million, the 3th loss-making year in a row.
- The share count rose 16.9% in the year.
- Shareholders' equity is negative: -$38 million.
Celularity Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 27−51.0%100% | 54+138%100% | 23+26.7%100% | 18−15.7%100% | 21+49.4%100% | 14—100% | — | |
| Cost of revenue | 20+33.9%75.6% | 15−6.4%27.6% | 16—70.3% | — | — | — | — | |
| Gross profit | — | — | 6.8—29.7% | −1.7−114%−9.4% | 12+25.0%54.8% | 9.3—65.5% | — | |
| Research and development | 15−13.6%56.6% | 17−42.9%32.1% | 30−61.1%134% | 78−11.3%436% | 88+67.6%414% | 53—369% | — | |
| Selling, general and administrative | 51−12.6%193% | 59+16.0%108% | 51−23.4%222% | 66−7.5%367% | 71+128%334% | 31—219% | — | |
| Operating income | −61—−231% | −38—−70.7% | −192—−844% | −26—−142% | −109—−511% | −152r−4.2—−1064% | −1.7r−0.6—— | |
| Interest and finance income | — | — | — | — | — | 1.8−52.6%12.5% | 3.8—— | |
| Other non-operating income (expense) | −30—−115% | −20—−36.0% | −4.0−110%−17.6% | 40+344%221% | 9.0—42.0% | −61r1.8−841%−427% | 8.2r3.7—— | |
| Income before tax | −92—−345% | −58—−107% | −196−1482%−862% | 14—79.0% | −100—−469% | −213r−2.4−3352%−1491% | 6.5r3.2—— | |
| Income tax | 0.0—0.0% | — | 0.0−23.1%0.0% | 0.0−35.0%0.1% | 0.0—0.1% | −4.7r0.2−803%−32.9% | 0.7—— | |
| Income from continuing operations | −61—−231% | −38—−70.7% | −192—−844% | −26—−142% | −109—−511% | −152—−1064% | — | |
| Net income including minority interests | — | — | −196−1483%−862% | 14—79.0% | −100—−469% | −208—−1458% | — | |
| Net income attributable to shareholders | −92—−345% | −58—−107% | −196−1483%−862% | 14—79.0% | −100—−469% | −208r−2.6−3642%−1458% | 5.9r2.5—— | |
| Earnings per share, basic | -3.59—— | -2.64—— | -11.02−1191%— | 1.01r0.10—— | -1.49—— | -11.31r-0.45−11410%— | 0.10r-0.03—— | |
| Earnings per share, diluted | -3.59—— | -2.64—— | -11.02−1260%— | 0.95r0.09—— | -1.49—— | -11.31r-0.45−11410%— | 0.10r-0.03—— | |
| Shares, weighted average (basic) | 26+16.9%— | 22+22.9%— | 18+27.3%— | 14r140−79.1%— | 67—— | — | — | |
| Shares, weighted average (diluted) | 26+16.9%— | 22+22.9%— | 18+18.9%— | 15r150−77.7%— | 67+264%— | 18r8.7−27.9%— | 26r8.0—— | |
| Balance sheet | ||||||||
| Cash and cash equivalents | 6.2+737%5.8% | 0.7+225%0.6% | 0.2−98.4%0.2% | 14−62.5%3.5% | 37−31.4%9.0% | 54r0.3+5823%12.6% | 0.9—0.3% | |
| Receivables | 4.7—4.3% | — | — | — | — | — | — | |
| Inventory | 0.6−89.4%0.5% | 5.4−6.0%4.1% | 5.8+8.4%4.0% | 5.3−44.4%1.3% | 9.50.0%2.3% | 9.5r3.9—2.2% | — | |
| Other current assets | 0.9+7.4%0.9% | 0.9−49.4%0.6% | 1.7−76.7%1.2% | 7.3+363000%1.8% | 0.0−99.8%0.0% | 0.9—0.2% | — | |
| Current assets | 12−40.1%11.5% | 21+3.9%15.5% | 20−40.9%13.8% | 34−43.3%8.4% | 59−18.1%14.3% | 72r0.4+7051%16.7% | 1.0—0.3% | |
| Property, plant and equipment | 56−9.4%52.0% | 62−9.2%46.4% | 68−10.3%47.1% | 76−16.5%18.9% | 91+0.6%21.9% | 90—20.9% | — | |
| Right-of-use (leased) assets | 11−1.0%10.0% | 11−1.5%8.2% | 11−15.8%7.6% | 13—3.3% | — | — | — | |
| Goodwill | 7.30.0%6.8% | 7.30.0%5.5% | 7.3−93.9%5.1% | 120−2.9%29.8% | 1230.0%29.8% | 123−3.0%28.6% | 127—43.6% | |
| Other intangible assets | 7.8−16.1%7.2% | 9.2−15.9%7.0% | 11−90.9%7.6% | 121−1.8%30.2% | 123−1.7%29.7% | 125—29.1% | — | |
| Total assets | 107−19.1%100% | 133−7.8%100% | 144−64.1%100% | 401−3.2%100% | 414−3.9%100% | 431r292+47.8%100% | 292—100% | |
| Accounts payable | 26+13.4%24.6% | 23+64.7%17.6% | 14+143%9.8% | 5.8−37.6%1.4% | 9.3+72.9%2.2% | 5.4r3.4+2464%1.3% | 0.2—0.1% | |
| Debt due within a year | — | — | 39—27.3% | — | — | — | — | |
| Current liabilities | 81+50.4%75.2% | 54−20.2%40.5% | 67+8.4%46.8% | 62+137%15.5% | 26−1.7%6.3% | 27r3.4+11545%6.2% | 0.2—0.1% | |
| Long-term debt | 34—31.5% | — | — | — | — | — | — | |
| Lease liabilities (non-current) | 27+1.3%25.1% | 27+1.4%20.0% | 26−6.5%18.2% | 28—7.0% | — | — | — | |
| Total liabilities | 145+17.4%135% | 124+20.3%93.3% | 103−49.1%71.5% | 202−35.8%50.4% | 315−23.7%76.0% | 412r14+1361%95.7% | 28r11—9.7% | |
| Retained earnings | −991—−924% | −900—−678% | −842—−585% | −645—−161% | −664—−160% | −564r−0.1−14626%−131% | 3.9r2.5—1.3% | |
| Shareholders' equity | −38−531%−35.5% | 8.8−78.4%6.7% | 41−79.4%28.5% | 199+100%49.6% | 99—24.0% | −531r5.0—−123% | −327r5.0—−112% | |
| Total equity | — | — | 41−79.4%28.5% | 199+100%49.6% | 99—24.0% | −531r5.0−10728%−123% | 5.0—1.7% | |
| Total liabilities and equity | 107−19.1%100% | 133−7.8%100% | 144−64.1%100% | 401−3.2%100% | 414−3.9%100% | 431r292+47.8%100% | 292—100% | |
| Shares outstanding | 29+27.9%— | 23+16.4%— | 19+30.1%— | 15r149−88.0%— | 124+571%— | 19+485%— | 3.2—— | |
| Cash-flow statement | ||||||||
| Depreciation and amortization | 7.3−7.9%27.5% | 7.9−15.0%14.6% | 9.3−1.2%40.9% | 9.4+7.0%52.5% | 8.8+7.9%41.3% | 8.2—57.2% | — | |
| Share-based compensation | 11−8.0%40.1% | 12—21.3% | 0r15−100%0.0% | 16−60.4%88.2% | 40+815%188% | 4.4—30.6% | — | |
| Cash from operating activities | −13—−49.9% | −6.4—−11.8% | −39—−170% | −138—−767% | −110—−516% | −63r−1.2—−443% | −1.1—— | |
| Capital expenditure | — | −0.2—−0.3% | −1.0—−4.6% | −5.2—−29.1% | −6.2—−29.1% | −28—−195% | — | |
| Cash from investing activities | — | 0.5—0.9% | −4.0—−17.8% | −5.2—−29.1% | −5.9—−27.7% | −13r0.6—−89.8% | −287—— | |
| Shares issued | 1.0—3.9% | — | — | — | — | — | — | |
| Shares bought back | — | — | — | — | — | −0.3—−1.8% | — | |
| Cash from financing activities | 19+178%70.2% | 6.7−72.2%12.4% | 24−79.9%106% | 120+21.6%667% | 99−3.4%462% | 102−64.7%714% | 289—— | |
| Change in cash | 5.4+563%20.3% | 0.8—1.5% | −19—−81.9% | −23—−129% | −17−167%−81.7% | 26r−0.6+2814%182% | 0.9—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 19−58.1%100% | 5.4−5.3%100% | 3.8−66.3%100% | 4.1*−77.4%100% | 5.3−43.2%100% | 5.7−52.6%100% | 11−22.2%100% | 18*+49.7%100% | 9.3+146%100% | 12—100% | 15—100% | 12*—100% | 3.8—100% | |
| Cost of revenue | 15−24.7%80.8% | 2.3−55.2%43.2% | 1.5−59.1%37.8% | 7.4*+0.4%180% | 3.9+0.5%73.9% | 5.2+147%91.4% | 3.6+117%31.1% | 7.3*−23.6%40.5% | 3.9+7.8%41.8% | 2.1—17.5% | 1.6—11.2% | 9.6*—79.3% | 3.6—95.1% | |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — | 2.5*—20.7% | 0.2—4.9% | |
| Research and development | 13−12.5%69.5% | 2.0−39.5%37.3% | 3.0−19.7%77.8% | 3.3*−12.6%81.6% | 4.6+17.4%87.0% | 3.4−11.8%58.4% | 3.7−36.2%32.6% | 3.8*—21.1% | 3.9−24.5%42.1% | 3.8—31.4% | 5.8—39.8% | — | 5.2—137% | |
| Selling, general and administrative | 38−30.8%206% | 4.9−60.9%90.9% | 9.2−35.7%238% | 15*−6.2%367% | 9.3−26.4%176% | 13−20.6%220% | 14+1.7%125% | 16*+22.9%88.6% | 13+17.7%136% | 16—131% | 14—95.6% | 13*—108% | 11—284% | |
| Operating income | −49—−264% | −4.2—−78.0% | −10—−263% | −22*—−537% | −13—−244% | −16—−277% | −10—−91.8% | −9.3*−170%−51.2% | −12—−124% | −10—−84.0% | −7.4—−50.2% | 13*—110% | −99—−2622% | |
| Interest and finance income | — | 0.0−82.3%0.2% | 0.1−18.4%1.6% | — | — | 0.1—1.1% | 0.1—0.7% | — | — | — | — | — | — | |
| Interest expense and finance costs | — | 0.2−90.9%3.3% | 0.4−85.6%9.2% | — | — | 1.9—33.9% | 2.4—21.3% | — | — | — | — | — | — | |
| Other non-operating income (expense) | 3.5—18.6% | 4.9—91.0% | 11—286% | −2.3*—−56.1% | −10—−193% | −8.7−335%−151% | −9.3—−81.1% | −4.0*—−22.1% | −4.6−185%−49.2% | 3.7—30.4% | −15—−99.7% | −3.8*—−31.0% | 5.4—142% | |
| Income before tax | −46—−246% | 0.7—13.0% | 0.9—22.7% | −24*—−594% | −23—−437% | −25—−428% | −20—−173% | −13*−239%−73.3% | −16—−173% | −6.5—−53.6% | −22—−150% | 9.6*—78.9% | −94—−2480% | |
| Income tax | — | — | — | — | — | — | — | — | 0—0.0% | 0—0.0% | 0—0.0% | 0.0*—0.1% | 0—0.0% | |
| Income from continuing operations | −49—−264% | −4.2—−78.0% | −10—−263% | −22*—−537% | −13—−244% | −16—−277% | −10—−91.8% | −9.3*−170%−51.2% | −12—−124% | −10—−84.0% | −7.4—−50.2% | 13*—110% | −99—−2622% | |
| Net income including minority interests | — | — | — | — | — | — | — | — | −16—−173% | −6.5—−53.6% | −22—−150% | 9.5*—78.8% | −94—−2480% | |
| Net income attributable to shareholders | −46—−246% | 0.7—13.0% | 0.9—22.7% | −24*—−594% | −23—−437% | −25—−428% | −20—−173% | −13*−239%−73.3% | −16—−173% | −6.5—−53.6% | −22—−150% | 9.5*—78.8% | −94—−2480% | |
| Earnings per share, basic | — | 0.02—— | 0.02—— | — | -0.88—— | -1.02—— | -0.84—— | — | -0.73—— | -0.30—— | -1.03—— | — | -4.98r-0.50—— | |
| Earnings per share, diluted | — | 0.02—— | 0.02—— | — | -0.88—— | -1.02—— | -0.84—— | — | -0.73—— | -0.30—— | -1.03—— | — | -4.98r-0.50—— | |
| Shares, weighted average (basic) | 29+21.6%— | 29+21.6%— | 29+23.5%— | — | 26+19.9%— | 24+9.9%— | 24+9.7%— | — | 22+16.7%— | 22—— | 21—— | — | 19r188—— | |
| Shares, weighted average (diluted) | 29+22.2%— | 29+22.2%— | 30+28.8%— | — | 26+19.9%— | 24+9.9%— | 24+9.7%— | — | 22+16.7%— | 22—— | 21—— | — | 19r188—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 0.6—0.6% | 0.6−32.1%0.6% | 0.4+25.6%0.4% | 6.2+737%5.8% | 0.1−9.8%0.1% | 0.9+84.8%0.7% | 0.3−84.6%0.2% | 0.7+225%0.6% | 0.1−51.3%0.1% | 0.5—0.3% | 1.9—1.3% | 0.2—0.2% | 0.3—0.2% | |
| Receivables | 4.7—4.9% | 4.7—4.9% | 4.8—4.8% | 4.7—4.3% | — | — | — | — | — | — | — | — | — | |
| Inventory | 0.7—0.7% | 0.7−83.7%0.7% | 0.5−92.3%0.5% | 0.6−89.4%0.5% | 2.6−35.3%2.2% | 4.4+51.3%3.7% | 6.2+67.4%4.8% | 5.4−6.0%4.1% | 4.0−19.7%3.1% | 2.9—2.2% | 3.7—2.6% | 5.8—4.0% | 4.9—3.1% | |
| Other current assets | 0.5—0.5% | 0.5−44.7%0.5% | 0.7+8.5%0.7% | 0.9+7.4%0.9% | 1.2−26.2%1.1% | 0.8−4.4%0.7% | 0.6−55.9%0.5% | 0.9−49.4%0.6% | 1.6−68.0%1.3% | 0.9—0.6% | 1.4—1.0% | 1.7—1.2% | 5.1—3.2% | |
| Current assets | 6.4—6.7% | 6.4−62.6%6.7% | 6.3−71.5%6.3% | 12−40.1%11.5% | 11−26.9%9.3% | 17−2.6%14.4% | 22−3.4%17.1% | 21+3.9%15.5% | 15−12.1%11.3% | 18—13.1% | 23—15.9% | 20—13.8% | 16—10.5% | |
| Property, plant and equipment | 53—55.5% | 53−9.0%55.5% | 55−9.3%54.9% | 56−9.4%52.0% | 57−9.5%50.1% | 59−9.4%48.8% | 60−9.3%46.7% | 62−9.2%46.4% | 63−10.5%49.1% | 65—47.8% | 66—46.1% | 68—47.1% | 71—44.9% | |
| Right-of-use (leased) assets | 11—11.1% | 11−0.8%11.1% | 11−0.9%10.8% | 11−1.0%10.0% | 11−1.1%9.4% | 11−1.2%9.0% | 11−1.3%8.4% | 11−1.5%8.2% | 11−1.6%8.4% | 11—8.0% | 11—7.6% | 11—7.6% | 11—7.0% | |
| Goodwill | 7.3—7.6% | 7.30.0%7.6% | 7.30.0%7.4% | 7.30.0%6.8% | 7.30.0%6.4% | 7.30.0%6.1% | 7.30.0%5.7% | 7.30.0%5.5% | 7.30.0%5.7% | 7.3—5.4% | 7.3—5.1% | 7.3—5.1% | 7.3—4.7% | |
| Other intangible assets | 6.3—6.6% | 6.3−25.6%6.6% | 7.4−16.8%7.4% | 7.8−16.1%7.2% | 8.1−15.5%7.1% | 8.5−14.9%7.1% | 8.9−15.1%6.9% | 9.2−15.9%7.0% | 9.6−16.7%7.5% | 10.0—7.4% | 10—7.3% | 11—7.6% | 12—7.4% | |
| Long-term investments | — | — | — | — | 2.9—2.5% | — | — | — | — | — | — | — | — | |
| Total assets | 96—100% | 96−20.0%100% | 99−22.8%100% | 107−19.1%100% | 114−11.3%100% | 120−11.2%100% | 129−10.4%100% | 133−7.8%100% | 129−18.0%100% | 135—100% | 144—100% | 144—100% | 157—100% | |
| Accounts payable | 15—15.2% | 15−40.3%15.2% | 25+7.7%25.2% | 26+13.4%24.6% | 25+59.7%21.5% | 24+77.8%20.3% | 23+79.6%18.1% | 23+64.7%17.6% | 15+19.1%12.0% | 14—10.1% | 13—9.0% | 14—9.8% | 13—8.2% | |
| Debt due within a year | — | — | — | — | — | 6.3−84.6%5.2% | 6.3−84.2%4.9% | — | 43—33.1% | 41—30.3% | 40—27.7% | 39—27.3% | — | |
| Current liabilities | 60—62.1% | 60−13.7%62.1% | 71+20.3%71.0% | 81+50.4%75.2% | 65−14.3%57.2% | 69+2.0%57.6% | 59−11.1%45.5% | 54−20.2%40.5% | 76−10.0%59.1% | 68—50.1% | 66—45.9% | 67—46.8% | 85—53.8% | |
| Long-term debt | — | — | — | 34—31.5% | 36—31.2% | — | — | — | — | — | — | — | — | |
| Lease liabilities (non-current) | 27—28.1% | 27+1.3%28.1% | 27+1.3%27.1% | 27+1.3%25.1% | 27+1.3%23.5% | 27+1.4%22.2% | 27+1.4%20.7% | 27+1.4%20.0% | 26+1.4%20.5% | 26—19.5% | 26—18.3% | 26—18.2% | 26—16.6% | |
| Total liabilities | 132—137% | 132−9.7%137% | 135+0.3%135% | 145+17.4%135% | 134+20.4%118% | 146+35.4%121% | 134+19.4%104% | 124+20.3%93.3% | 112−12.1%86.6% | 108—79.5% | 113—78.3% | 103—71.5% | 127—80.8% | |
| Retained earnings | −990—−1029% | −990—−1029% | −991—−996% | −991—−924% | −967—−847% | −944—−785% | −920—−713% | −900—−678% | −886—−688% | −870—−642% | −864—−601% | −842—−585% | −851—−542% | |
| Shareholders' equity | −36—−36.9% | −36—−36.9% | −35—−35.4% | −38−531%−35.5% | −20−216%−17.6% | −25−192%−21.2% | −5.5−118%−4.3% | 8.8−78.4%6.7% | 17−42.9%13.4% | 28—20.5% | 31—21.7% | 41—28.5% | 30—19.2% | |
| Total equity | — | — | — | — | — | — | — | — | 17−42.9%13.4% | 28—20.5% | 31—21.7% | 41—28.5% | 30—19.2% | |
| Total liabilities and equity | 96—100% | 96−20.0%100% | 99−22.8%100% | 107−19.1%100% | 114−11.3%100% | 120−11.2%100% | 129−10.4%100% | 133−7.8%100% | 129−18.0%100% | 135—100% | 144—100% | 144—100% | 157—100% | |
| Shares outstanding | 29—— | 29+19.0%— | 29+21.9%— | 29+27.9%— | 28+28.3%— | 25+12.2%— | 24+9.8%— | 23+16.4%— | 22−88.6%— | 22—— | 22—— | 19—— | 194—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 6.8−4.2%36.2% | 1.5*−16.1%28.3% | 1.6−12.9%41.5% | 1.8*−3.9%43.9% | 1.8*+20.1%34.5% | 1.8*+19.1%32.0% | 1.8−14.9%16.1% | 1.9*−18.3%10.3% | 1.5−15.1%16.3% | 1.5—12.7% | 2.2—14.7% | 2.3*—19.0% | 1.8—47.3% | |
| Share-based compensation | 6.1−27.3%32.5% | 0.8+681%15.5% | 1.2−52.9%32.3% | 3.5*+19.6%85.7% | 0.5−82.4%8.9% | 0.1−96.4%1.9% | 2.6−11.1%23.1% | 2.9*−17.7%16.2% | 2.7−25.7%28.7% | 3.0—24.7% | 3.0—20.2% | 3.6*—29.5% | 3.6—95.0% | |
| Cash from operating activities | −8.9—−47.8% | −1.1*—−20.4% | 1.4—37.6% | −5.1*−420%−124% | −4.2*—−78.7% | −1.0*—−17.4% | −3.0—−26.2% | 1.6*—8.8% | −0.1*—−1.5% | −3.4*—−28.5% | −4.4—−30.0% | −4.3*—−35.8% | −8.3*—−220% | |
| Capital expenditure | — | — | — | — | — | — | — | −0.1r−0.1*—−0.5% | 0r−0.0*—0.0% | −0.0*—−0.3% | −0.0—−0.3% | −0.6*—−4.8% | −0.2*—−6.0% | |
| Intangible assets bought | — | −0.7—−12.9% | — | — | — | — | — | — | — | — | — | — | — | |
| Cash from investing activities | — | — | — | — | — | — | — | −1.6r−1.6*—−8.8% | 0r−0.0*—0.0% | 2.1*—17.7% | −0.0—−0.3% | −0.6*—−4.8% | −0.2*—−6.0% | |
| Shares issued | — | — | — | 0*—0.0% | −1.4*—−27.0% | 0*—0.0% | 2.5—21.5% | — | — | — | — | — | — | |
| Cash from financing activities | 8.4+85.6%44.9% | 1.0*−37.2%18.9% | −7.3−416%−191% | 11*+1645%273% | 3.5*—65.8% | 1.6*—28.4% | 2.3−62.7%20.3% | 0.6*—3.5% | −0.1*−101%−0.8% | −0.1*—−0.7% | 6.2—42.4% | −0.0*—−0.1% | 5.7*—152% | |
| Change in cash | −0.5−242%−2.9% | −0.1*−113%−1.5% | −5.9—−153% | 6.1*+847%149% | −0.7*—−12.9% | 0.6*—11.0% | −0.7−138%−5.9% | 0.6r0.7*—3.6% | −0.2r−0.3*—−2.4% | −1.4*—−11.5% | 1.8—12.2% | −4.9*—−40.7% | −2.8*—−74.2% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Celularity Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Product(total)$13 M50%-63%
- License Royalty and Other$8 M30%-42%
- Service(total)$5 M20%+5.6%
Business segments
- Degenerative Disease$17 M65%-64%
- Biobanking$5 M20%+5.6%
- Cell Therapy$4 M14%+452%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Events at Celularity Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 2 · Directors and officers 11 · Material agreement 12 · New debt 6 · Unregistered share sale 6 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 1
| Filed | What happened | Filing |
|---|---|---|
| Directors and officers | 8-K | |
| Directors and officersMaterial agreementNew debtUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Directors and officersMaterial agreementNew debt | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Material agreementNew debt | 8-K | |
| Directors and officersMaterial agreementNew debtShareholder rights changed | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementUnregistered share saleBylaws or fiscal year changed | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Sep 29, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2025 | $2 M | Private placement after listing | $2 to $10 million | 1 | equity, options | SEC |
| Jul 2025 | $2 M | Private placement after listing | $2 to $10 million | 1 | equity, options | SEC |
| Jul 2025 | $1 M | Private placement after listing | Under $2 million | 14 | equity, options | SEC |
| Jul 2025 | $7 M | Private placement after listing | $2 to $10 million | 1 | debt, options | SEC |
| May 2022 | $30 M | Private placement after listing | $10 to $50 million | 1 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Celularity Inc.#
$20 K spent on lobbying the US Congress and federal agencies in 2023, most often on health issues.
- Health Issues2 reports
Lobbying firms hired in 2023
DA VINCI GROUP $20 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2023 | $20 K | — | 2 |
| 2022 | $40 K | — | 4 |
| 2021 | $30 K | — | 3 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Celularity, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
How Celularity Inc. compares in Biotechnology
- Market cap$28 M · higher than 20% of 726
- Revenue$27 M · higher than 52% of 647
- Net margin-245.8% · higher than 23% of 408
- Revenue growth-51.0% · higher than 18% of 438
- Price / sales1.5× · lower than 91% of 339
- FCF yield-23.8% · higher than 40% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Celularity Inc.🇺🇸 | $28 M | — | -245.8% | -51.0% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on July 2022
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Celularity Inc.? Verify and update this profile — free
Show Celularity Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.